Disrupted Central Inhibition after Transcranial Magnetic Stimulation of Motor Cortex in Schizophrenia with Long-Term Antipsychotic Treatment

Table 1

Sociodemographic and clinical parameters of subjects with schizophrenia and controls.

Scales	PANSS	AIMS	BAS	SAS	AP (mg)	DUI	AGE	Subtype	Calgary
					(CPZ equiv.)	(years)	(years)	(𝑛)
Groups; Control (𝑛=9)							36.1/
𝑚/sd							8.43
Total (𝑛=11)	74.09/	7.36/	1.18/	1.27/	638.84/	17.27/	42.09	Paranoid (3)	5.55 ± 2.8
𝑚/sd	15.06	5.78	1.17	1.19	439.90	12.16	13.67	Undiffer. (8)
CA (𝑛=6)	73.83/	10.67/	1.83/	1.33/	700.00/	22.50/	49.50/	Paranoid (1)	4.83 ± 3.31
𝑚/sd	17.53	5.96	1.17	1.51	496.5	12.63	12.45	Undiffer. (5)
AA (𝑁=5)	74.40/	3.40/	0.40/	1.20/	565.45/	11.00/	33.20/	Paranoid (2)	6.40 ± 2.07
𝑚/sd	13.51	1.82	0.55	0.84	404.03	8.94	9.60	Undiffer. (3)
Analysis between users of CA and AA (Mann-Whitney test)
𝑈 test	14.5	4.5	4.5	13	11	5.5	4		8
𝑃 value	0.93	0.05	0.05	0.93	0.54	0.08	0.05		0.25
Analysis between controls, AA, and CA (Kruskal-Wallis test)
Chi-square							5.94
𝑃-value							0.051

Total: all subjects with schizophrenia; CA: subjects with schizophrenia, users of conventional neuroleptics; AA: subjects with schizophrenia, users of atypical neuroleptics; daily dose of antipsychotics (CPZ, mg in 100 mg chlorpromazine equivalents); DUI: duration of illness (in years) and age (in years) of the subjects with schizophrenia; 𝑚: mean value, sd: standard deviation; 𝑛: number of subjects; PANSS: Positive and Negative Syndrome Scale (total score); AIMS: Abnormal Involuntary Movement Scale; SAS: Simpson and Angus Scale for Extrapyramidal Signs; BAS: Barnes Akathisia Rating Scale (global clinical assessment of akathisia); undiffer./paranoid: undifferentiated/paranoid subtype of schizophrenia; Analysis: statistical analysis of the differences between the users of CA and AA (Mann-Whitney 𝑈 test, 𝑃: probability, level of significance was set <0.05).